Frequent <i>Klebsiella pneumoniae</i> Urinary Tract Infections in a Patient Treated with Ruxolitinib

• Egile Nagusiak: Ramy M. Hanna (Egilea), Maham Khalid (Egilea), Lama Abd El-Nour (Egilea), Umut Selamet (Egilea)
• Formatua: Liburua
• Argitaratua: MDPI AG, 2019-09-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Ruxolitinib is a targeted agent that inhibits Janus 2 Kinase and is approved for use in Polycythemia Vera and Primary Myelofibrosis. Its mechanism of action involves inhibition of cellular proliferation via the Janus kinase/signal transducer and activator of transcription proteins pathway. Ruxolitin...